{"_links": {"parentPackage": {"href": "/mdr/ct/packages/sdtmct-2015-12-18", "title": "SDTM Controlled Terminology Package 24 Effective 2015-12-18", "type": "Terminology"}, "priorVersion": {"href": "/mdr/ct/packages/sdtmct-2015-09-25/codelists/C66738", "title": "CDISC SDTM Trial Summary Parameter Short Name Terminology", "type": "Code List"}, "rootItem": {"href": "/mdr/root/ct/sdtmct/codelists/C66738", "title": "Version-agnostic anchor resource for codelist C66738", "type": "Root Value Domain"}, "self": {"href": "/mdr/ct/packages/sdtmct-2015-12-18/codelists/C66738", "title": "CDISC SDTM Trial Summary Parameter Short Name Terminology", "type": "Code List"}}, "conceptId": "C66738", "definition": "The test code for an individual characteristic of a clinical trial, e.g. description of trial design, trial blinding schema, and primary objective of trial.", "extensible": "true", "name": "Trial Summary Parameter Test Code", "preferredTerm": "CDISC SDTM Trial Summary Parameter Short Name Terminology", "submissionValue": "TSPARMCD", "synonyms": ["Trial Summary Parameter Test Code"], "terms": [{"conceptId": "C98703", "definition": "Actual number of subjects enrolled; may include subjects who were not randomized.", "preferredTerm": "Actual Subject Number", "submissionValue": "ACTSUB", "synonyms": ["Actual Number of Subjects"]}, {"conceptId": "C98704", "definition": "Indicate if the study includes a prospectively planned opportunity for modification of one or more specified aspects of the study design and hypotheses based on analysis of data (usually interim data) from subjects in the study.", "preferredTerm": "Adaptive Design", "submissionValue": "ADAPT", "synonyms": ["Adaptive Design"]}, {"conceptId": "C49703", "definition": "The addition of a therapeutic product to the existing regimen in a clinical trial, where both entities remain as discrete products.", "preferredTerm": "Test Product Added to Existing Treatment", "submissionValue": "ADDON", "synonyms": ["Added on to Existing Treatments"]}, {"conceptId": "C49694", "definition": "The anticipated maximum age of the subjects to be entered in a clinical trial. (NCI)", "preferredTerm": "Planned Maximum Age of Subjects", "submissionValue": "AGEMAX", "synonyms": ["Planned Maximum Age of Subjects"]}, {"conceptId": "C49693", "definition": "The anticipated minimum age of the subjects to be entered in a clinical trial. (NCI)", "preferredTerm": "Planned Minimum Age of Subjects", "submissionValue": "AGEMIN", "synonyms": ["Planned Minimum Age of Subjects"]}, {"conceptId": "C68612", "definition": "A therapeutically active agent that is intended to provide reference measurements for the experimental protocol of a clinical trial.", "preferredTerm": "Active Comparator Drug", "submissionValue": "COMPTRT", "synonyms": ["Comparative Treatment Name"]}, {"conceptId": "C98715", "definition": "The protocol specified minimum amount of time needed to meet the definition of a confirmed response to treatment.", "preferredTerm": "Confirmed Response Minimum Duration", "submissionValue": "CRMDUR", "synonyms": ["Confirmed Response Minimum Duration"]}, {"conceptId": "C85582", "definition": "The literal identifier of the therapy or medication that is currently being given per protocol.", "preferredTerm": "Current Therapy", "submissionValue": "CURTRT", "synonyms": ["Current Therapy or Treatment"]}, {"conceptId": "C98718", "definition": "Text that describes the cutoff date.", "preferredTerm": "Data Cutoff Date Description", "submissionValue": "DCUTDESC", "synonyms": ["Data Cutoff Description"]}, {"conceptId": "C98717", "definition": "A date which indicates any data collected by this date will be used for analysis.", "preferredTerm": "Data Cutoff Date", "submissionValue": "DCUTDTC", "synonyms": ["Data Cutoff Date"]}, {"conceptId": "C25488", "definition": "The amount of drug administered to a patient or test subject at one time or the total quantity administered. [AMA Manual of Style] (CDISC Glossary)", "preferredTerm": "Dose", "submissionValue": "DOSE", "synonyms": ["Dose Level", "Dose per Administration"]}, {"conceptId": "C89081", "definition": "The number of doses administered per a specific interval.", "preferredTerm": "Dose Frequency", "submissionValue": "DOSFRQ", "synonyms": ["Dosing Frequency"]}, {"conceptId": "C73558", "definition": "The unit of measure for the dosage form.", "preferredTerm": "Dosage Form Unit", "submissionValue": "DOSU", "synonyms": ["Dose Units"]}, {"conceptId": "C117960", "definition": "A standard from which a judgment concerning a medical diagnosis can be established.", "preferredTerm": "Diagnostic Criteria", "submissionValue": "DXCRIT", "synonyms": ["Diagnostic Criteria"]}, {"conceptId": "C119560", "definition": "Indicates whether assessors of ECGs for this study were blinded to subject identity, timing and treatment.", "preferredTerm": "ECG Evaluator Blinding Parameters", "submissionValue": "EGBLIND", "synonyms": ["ECG Reading Blinded"]}, {"conceptId": "C119561", "definition": "Indicates whether the 10-second ECGs for this study were extracted from a continuous recording.", "preferredTerm": "ECG Continuous Monitoring Indicator", "submissionValue": "EGCTMON", "synonyms": ["ECG Continuous Monitoring"]}, {"conceptId": "C119562", "definition": "The ECG lead which was planned to be used for ECG interval measurements for this study.", "preferredTerm": "ECG Planned Primary Lead for Study", "submissionValue": "EGLEADPR", "synonyms": ["ECG Planned Primary Lead"]}, {"conceptId": "C119563", "definition": "Indicates whether all ECG interval measurements for the study were based on the same lead.", "preferredTerm": "ECG Used Same Lead Indicator", "submissionValue": "EGLEADSM", "synonyms": ["ECG Used Same Lead"]}, {"conceptId": "C119564", "definition": "The degree of automation involved in assessing the ECGs for this study.", "preferredTerm": "ECG Read Method Degree of Automation", "submissionValue": "EGRDMETH", "synonyms": ["ECG Read Method"]}, {"conceptId": "C119565", "definition": "Indicates whether this study includes replicate ECGs for time points during the baseline portion of the study.", "preferredTerm": "ECG Replicates at Baseline Indicator", "submissionValue": "EGREPLBL", "synonyms": ["ECG Replicates at Baseline"]}, {"conceptId": "C119566", "definition": "Indicates whether this study includes replicate ECGs for time points during the on-treatment portion of the study.", "preferredTerm": "ECG Replicates On-Treatment Indicator", "submissionValue": "EGREPLTR", "synonyms": ["ECG Replicates On-Treatment"]}, {"conceptId": "C119582", "definition": "The algorithm used to identify the end of the T wave for ECGs for this study.", "preferredTerm": "ECG T Wave Algorithm", "submissionValue": "EGTWVALG", "synonyms": ["ECG Twave Algorithm"]}, {"conceptId": "C98770", "definition": "The country name of planned study facility which has received IRB approval.", "preferredTerm": "Planned Country of Investigational Site", "submissionValue": "FCNTRY", "synonyms": ["Planned Country of Investigational Sites"]}, {"conceptId": "C123629", "definition": "An indication as to whether the study involves an FDA-regulated device.", "preferredTerm": "FDA-Regulated Device Study Indicator", "submissionValue": "FDADEIND", "synonyms": ["FDA-Regulated Device Study Indicator"]}, {"conceptId": "C123630", "definition": "An indication as to whether the study involves an FDA-regulated drug.", "preferredTerm": "FDA-Regulated Drug Study Indicator", "submissionValue": "FDADRIND", "synonyms": ["FDA-Regulated Drug Study Indicator"]}, {"conceptId": "C98737", "definition": "Indicate if persons who have not had the condition(s) being studied or otherwise related conditions or symptoms, as specified in the eligibility requirements, may participate in the study.", "preferredTerm": "Healthy Subject Indicator", "submissionValue": "HLTSUBJI", "synonyms": ["Healthy Subject Indicator"]}, {"conceptId": "C112038", "definition": "The condition, disease or disorder that the clinical trial is intended to investigate or address.", "preferredTerm": "Trial Indication", "submissionValue": "INDIC", "synonyms": ["Trial Indication"]}, {"conceptId": "C98746", "definition": "The trial design developed to compare treatment groups.", "preferredTerm": "Intervention Model", "submissionValue": "INTMODEL", "synonyms": ["Intervention Model"]}, {"conceptId": "C98747", "definition": "The kind of product or procedure studied in a trial.", "preferredTerm": "Intervention Type", "submissionValue": "INTTYPE", "synonyms": ["Intervention Type"]}, {"conceptId": "C49697", "definition": "Planned length of observation for a single subject.", "preferredTerm": "Trial Length", "submissionValue": "LENGTH", "synonyms": ["Trial Length"]}, {"conceptId": "C124455", "definition": "The name of the country within which the final product under study is produced.", "preferredTerm": "Country of Manufacture", "submissionValue": "MNFCNTRY", "synonyms": ["Country of Manufacture"]}, {"conceptId": "C98771", "definition": "The planned number of intervention groups.", "preferredTerm": "Planned Number of Arms", "submissionValue": "NARMS", "synonyms": ["Planned Number of Arms"]}, {"conceptId": "C85826", "definition": "The principal purpose of the trial.", "preferredTerm": "Trial Primary Objective", "submissionValue": "OBJPRIM", "synonyms": ["Trial Primary Objective"]}, {"conceptId": "C85827", "definition": "The auxiliary purpose of the trial.", "preferredTerm": "Trial Secondary Objective", "submissionValue": "OBJSEC", "synonyms": ["Trial Secondary Objective"]}, {"conceptId": "C98724", "definition": "Exploratory measures that will be used to evaluate the intervention(s) or, for observational studies, that are exploratory of the study.", "preferredTerm": "Exploratory Outcome Measure", "submissionValue": "OUTMSEXP", "synonyms": ["Exploratory Outcome Measure"]}, {"conceptId": "C98772", "definition": "The primary measurement(s) or observation(s) used to measure the effect of experimental variables in a study, or for observational studies, to describe patterns of diseases or traits or associations with exposures, risk factors or treatment. These are the outcome measures used to assess the primary objective(s).", "preferredTerm": "Primary Outcome Measure", "submissionValue": "OUTMSPRI", "synonyms": ["Primary Outcome Measure"]}, {"conceptId": "C98781", "definition": "Other key measures that will be used to evaluate the intervention(s) or, for observational studies, that are a focus of the study. These are the outcome measures used to assess the secondary objective(s).", "preferredTerm": "Secondary Outcome Measure", "submissionValue": "OUTMSSEC", "synonyms": ["Secondary Outcome Measure"]}, {"conceptId": "C98768", "definition": "The pharmacological class of the investigational product.", "preferredTerm": "Pharmacological Class of Investigational Therapy", "submissionValue": "PCLAS", "synonyms": ["Pharmacological Class of Invest. Therapy"]}, {"conceptId": "C123631", "definition": "An indication as to whether the study is a pediatric postmarket study.", "preferredTerm": "Pediatric Postmarket Study Indicator", "submissionValue": "PDPSTIND", "synonyms": ["Pediatric Postmarket Study Indicator"]}, {"conceptId": "C123632", "definition": "An indication as to whether the study is a pediatric study.", "preferredTerm": "Pediatric Study Indicator", "submissionValue": "PDSTIND", "synonyms": ["Pediatric Study Indicator"]}, {"conceptId": "C49692", "definition": "The planned number of subjects to be entered in a clinical trial. (NCI)", "preferredTerm": "Planned Subject Number", "submissionValue": "PLANSUB", "synonyms": ["Anticipated Enrollment", "Planned Enrollment", "Planned Number of Subjects", "Target Enrollment"]}, {"conceptId": "C25196", "definition": "The process of assigning trial subjects to treatment or control groups using an element of chance to determine the assignments in order to reduce bias. NOTE: Unequal randomization is used to allocate subjects into groups at a differential rate; for example, three subjects may be assigned to a treatment group for every one assigned to the control group. [ICH E6 1.48] See also balanced study. (CDISC glossary)", "preferredTerm": "Randomization", "submissionValue": "RANDOM", "synonyms": ["Trial is Randomized"]}, {"conceptId": "C98775", "definition": "The randomization quotient is the number of planned subjects to be exposed to investigational therapy, independent of dose or other factors, divided by the total number of planned subjects.", "preferredTerm": "Randomization Quotient", "submissionValue": "RANDQT", "synonyms": ["Randomization Quotient"]}, {"conceptId": "C98714", "definition": "Identification numbers assigned to the protocol by clinicaltrials.gov, EudraCT, or other registries.", "preferredTerm": "Clinical Trial Registry Identifier", "submissionValue": "REGID", "synonyms": ["Registry Identifier"]}, {"conceptId": "C117961", "definition": "A standard from which a judgment concerning a disease relapse can be established.", "preferredTerm": "Relapse Criteria", "submissionValue": "RLPSCRIT", "synonyms": ["Relapse Criteria"]}, {"conceptId": "C38114", "definition": "The course by which a substance was administered in order to reach the site of action in the body.", "preferredTerm": "Route of Administration", "submissionValue": "ROUTE", "synonyms": ["Route of Administration"]}, {"conceptId": "C98783", "definition": "The protocol specified minimum amount of time needed to meet the definition of stable disease.", "preferredTerm": "Stable Disease Minimum Duration", "submissionValue": "SDMDUR", "synonyms": ["Stable Disease Minimum Duration"]}, {"conceptId": "C90462", "definition": "Final date on which data was collected for any subject (Date/Time of End of Participation, RFPENDTC) based on the protocol.", "preferredTerm": "Study End Date", "submissionValue": "SENDTC", "synonyms": ["Study End Date"]}, {"conceptId": "C117962", "definition": "A standard from which a judgment concerning the severity of an event, disease or condition can be established.", "preferredTerm": "Severity Criteria", "submissionValue": "SEVCRIT", "synonyms": ["Severity Criteria"]}, {"conceptId": "C49696", "definition": "The specific sex, either male, female, or mixed of the subject group being studied. (NCI)", "preferredTerm": "Sex of Study Group", "submissionValue": "SEXPOP", "synonyms": ["Sex of Participants"]}, {"conceptId": "C70793", "definition": "An entity that is responsible for the initiation, management, and/or financing of a clinical study.", "preferredTerm": "Clinical Study Sponsor", "submissionValue": "SPONSOR", "synonyms": ["Clinical Study Sponsor", "Sponsor", "Study Sponsor"]}, {"conceptId": "C69208", "definition": "The earliest date of informed consent among any subject (Date/Time of Informed Consent, RFICDTC) that enrolled in the study. For studies conducted without informed consent (ie. emergency use) use the date of treatment. Dates for subjects who were screen failures are not included.", "preferredTerm": "Study Start Date", "submissionValue": "SSTDTC", "synonyms": ["Study Start Date"]}, {"conceptId": "C49698", "definition": "The rule, regulation and/or condition that determines the point in time when a clinical trial will be terminated. (NCI)", "preferredTerm": "Study Stop Rule", "submissionValue": "STOPRULE", "synonyms": ["Study Stop Rules"]}, {"conceptId": "C16153", "definition": "Selected pre-treatment factors by which patients are segregated to assure balance of these factors before randomization to the intervention arms of a clinical protocol.", "preferredTerm": "Stratification Factors", "submissionValue": "STRATFCT", "synonyms": ["Stratification Factor"]}, {"conceptId": "C15320", "definition": "Describes the role the study plays in determining the interventions a subject receives.", "preferredTerm": "Study Design", "submissionValue": "STYPE", "synonyms": ["Study Type"]}, {"conceptId": "C49658", "definition": "The name of a code list that contains terms to define the type of blinding for the trial. (NCI)", "preferredTerm": "Trial Blinding Schema", "submissionValue": "TBLIND", "synonyms": ["Trial Blinding Schema"]}, {"conceptId": "C49647", "definition": "Comparator against which the study treatment is evaluated (e.g., concurrent (placebo, no treatment, dose-response, active), external (historical, published literature).", "preferredTerm": "Control Type", "submissionValue": "TCNTRL", "synonyms": ["Control Type"]}, {"conceptId": "C49650", "definition": "A grouping of individuals on the basis of a shared procedure or disease, or lack thereof (e.g. healthy volunteers, type 2 diabetic subjects, subjects with renal cell cancer). Standardized naming systems are available that define the groups within which a subject should be placed. (NCI)", "preferredTerm": "Diagnosis Group", "submissionValue": "TDIGRP", "synonyms": ["Diagnosis Group"]}, {"conceptId": "C49652", "definition": "The name of a code list that contains terms to define the type of trial, e.g. cure or prevention. (NCI)", "preferredTerm": "Clinical Study by Intent", "submissionValue": "TINDTP", "synonyms": ["Trial Indication Type"]}, {"conceptId": "C49802", "definition": "The name of a clinical trial. (NCI)", "preferredTerm": "Trial Title", "submissionValue": "TITLE", "synonyms": ["Trial Title"]}, {"conceptId": "C48281", "definition": "Clinical trials are broken into three or four phases: Phase I tests a new drug or treatment for safety in a small group; Phase II expands the study to a larger group of people; Phase III expands the study to an even larger group of people to measure whether the treatment actually benefits patients, and whether its benefits exceed its risks; and Phase IV takes place after the drug or treatment has been licensed and marketed. (NCI)", "preferredTerm": "Trial Phase", "submissionValue": "TPHASE", "synonyms": ["Trial Phase Classification"]}, {"conceptId": "C41161", "definition": "The investigational product under study.", "preferredTerm": "Protocol Agent", "submissionValue": "TRT", "synonyms": ["Investigational Therapy or Treatment"]}, {"conceptId": "C49660", "definition": "The type of clinical trial performed e.g. efficacy, safety. (NCI)", "preferredTerm": "Trial Type", "submissionValue": "TTYPE", "synonyms": ["Trial Type"]}]}